Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a research report issued to clients and investors on Sunday. The firm set a “sell” rating on the biotechnology company’s stock.

Cyclacel Pharmaceuticals Stock Performance

Shares of Cyclacel Pharmaceuticals stock opened at $0.32 on Friday. The firm has a market capitalization of $2.01 million, a price-to-earnings ratio of -0.03 and a beta of 0.28. Cyclacel Pharmaceuticals has a fifty-two week low of $0.29 and a fifty-two week high of $4.00. The stock has a 50 day moving average of $0.34 and a 200 day moving average of $0.54.

Insiders Place Their Bets

In other Cyclacel Pharmaceuticals news, CEO David E. Lazar sold 194,628,820 shares of the company’s stock in a transaction on Wednesday, February 26th. The stock was sold at an average price of $0.03, for a total transaction of $5,838,864.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 23.97% of the stock is owned by insiders.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.